癌症相关心力衰竭发生风险、治疗及管理

Risk,treatment and management of cancer-related heart failure

心力衰竭的患病率全球呈上升趋势,主要由于人群老龄化和疾病治疗上的巨大进步使带病生存的患者人数增加。我国最新流行病学研究显示,在≥35岁居民中心力衰竭患病率为1.3%,大约有890万患者。心力衰竭患者的生活质量非常差,出现呼吸困难、乏力、浮肿等症状,随着疾病的发展,症状会逐渐加重,甚至影响生命。近年随着肿瘤医学的发展,越来越多的肿瘤患者接受治疗后带肿瘤生存,但化学治疗、放射治疗所致的心脏毒性副作用随着时间的推移逐渐显现,心血管疾病尤其是心力衰竭显著增加。肿瘤合并心力衰竭严重影响患者的预后以及生活质量,肿瘤合并心力衰竭的治疗有其特点,本文就肿瘤相关心力衰竭以及管理作一综述。

The prevalence of heart failure is on the rise globally,mainly due to an aging population and the increase in the number of patients living with the disease as a result of dramatic advances in disease treatment.China's latest epidemiological study shows that the prevalence of heart failure was 1.3%in residents aged≥35 years,or about 8.9 million patients.The quality of life of patients with heart failure is very poor,there will be dyspnea,fatigue,puffiness and other symptoms,with the development of the disease,symptoms can get progressively worse and even life threatening.In recent years,with the development of oncology medicine,more and more cancer patients survive with cancer after treatment,but the toxic side effects on heart caused by chemotherapy and radiotherapy gradually appear over time,and cardiovascular disease,especially heart failure,increases significantly.Tumor combined heart failure seriously affects the prognosis and quality of life of patients,and the treatment of tumor combined heart failure has its characteristics.This article reviews cancer-related heart failure and management.